HCPCS code J2779: Susvimo ranibizumab, per 0.1 mg2026 Medicare rate & RVUs in Oregon
Reports ranibizumab delivered through the Susvimo intravitreal implant for neovascular age-related macular degeneration, measured in 0.1 mg units.
CMS doesn’t publish an office rate for J2779 in Oregon.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J2779 covers
J2779 represents ranibizumab administered through the Susvimo implant, a refillable intravitreal drug delivery system used to treat neovascular, or wet, age-related macular degeneration. Retina specialists and other ophthalmologists implant the device and provide its subsequent refills in ophthalmic surgical or procedure settings. The drug enters the eye through the implant rather than through a conventional intravitreal injection at each treatment visit.
CMS assigns physician fee schedule status E, meaning the code is excluded from the physician fee schedule. When Medicare covers the drug, payment is under another payment method; the HCPCS pricing method identifies it as a Part B drug generally paid using CMS quarterly Average Sales Price files. Coverage is left to the Medicare contractor’s judgment. Each billing unit represents 0.1 mg of ranibizumab. Report the drug separately from the procedure performed to insert or refill the implant, using the applicable procedure coding.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J2779 pays more and less in Oregon
| Payment locality | Office | Facility |
|---|---|---|
| Portland, OR | Unavailable | Unavailable |
| Rest of Oregon | Unavailable | Unavailable |
How the J2779 rate is calculated
Each of J2779’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J2779
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J2779
J2779 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J2779
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J2779 isn’t priced in this setting.
J2779 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J2778Ranibizumab injectionPer 0.1 mg
- Choose J2779 for ranibizumab delivered through Susvimo; J2778 represents ranibizumab administered by conventional intravitreal injection.
- J2777Faricimab injectionPer 0.1 mg
- J2777 identifies faricimab, a different drug. J2779 identifies ranibizumab administered through the Susvimo implant.
- 0770TVR-assisted therapyWith physiologic monitoring
- J2779 reports the ranibizumab drug in 0.1 mg units. CPT 0770T describes the implant refill and maintenance service, not the drug.
J2779 billing questions
How is J2779 different from J2778?
J2779 is ranibizumab delivered through the Susvimo implant. J2778 is the code for ranibizumab given by conventional intravitreal injection.
How many units should be reported?
Each J2779 unit represents 0.1 mg of ranibizumab. Calculate units from the amount administered through the implant.
Does J2779 include implant insertion or refill services?
No. J2779 identifies the drug; report the applicable procedure service separately when performed. CPT 67027 describes insertion of an intravitreal drug delivery system, and CPT 0770T describes refill and maintenance of an intravitreal implant drug delivery system.
What is Medicare’s payment treatment for J2779?
CMS assigns status E, excluding J2779 from the physician fee schedule. When covered, Medicare generally pays it as a Part B drug using the quarterly ASP drug pricing files; coverage is determined by the Medicare contractor.
Does J2779 require a particular modifier?
J2779 identifies the drug and its 0.1 mg billing unit, not the eye or the implant procedure. Document the administered amount and use the applicable coding for the procedure performed.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J2779 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist